questionText: To ask the Secretary of State for Health and Social Care, whether the NHS plans to fund abiraterone for patients with high-risk non-metastatic prostate cancer.
answerText: The Department has had no such discussions. Abiraterone does not have a marketing authorisation for use in the treatment of high-risk, non-metastatic prostate cancer and has not been evaluated for that indication by the National Institute for Health and C...
heading: Abiraterone